ACCELERON PHARMA INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
ACCELERON PHARMA INC. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $3.73 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2020-11-05
- 2020-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month $3.73M.
- 2019-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month |
|---|---|
| 2020-09-30 | $3.73M 10-Q · filed 2020-11-05 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 |